OBJECTIVE: To compare the costs and benefits of pneumococcal conjugate vaccination compared with no vaccination from the perspectives of the health care system and society. METHODS: Using data from established sources, we estimated the incidence and mortality due to invasive pneumococcal disease, pneumonia, and acute otitis media (AOM) for a hypothetical birth cohort of children from birth to 5 years. RESULTS: A universal pneumococcal conjugate vaccination program was estimated capable of annually avoiding 1 047 cases of invasive disease, 58 226 cases of pneumonia, and 209 862 cases of AOM. When herd immunity effects were considered, the program prevented 1.3 million cases of pneumococcal disease and over 7 000 pneumococcal deaths. At a vaccination cost of R$ 51.12 (US$ 26.35) per dose, vaccination would cost annually R$ 4 289 (US$ 2,211) per disability-adjusted life years averted. This does not take into account herd immunity effects. CONCLUSIONS: At the current vaccine price, conjugate vaccination could be a cost-effective investment compared to other options to control childhood diseases. Further analysis is required to determine whether vaccination at the current price is affordable to Brazil.
OBJECTIVE: To compare the costs and benefits of pneumococcal conjugate vaccination compared with no vaccination from the perspectives of the health care system and society. METHODS: Using data from established sources, we estimated the incidence and mortality due to invasive pneumococcal disease, pneumonia, and acute otitis media (AOM) for a hypothetical birth cohort of children from birth to 5 years. RESULTS: A universal pneumococcal conjugate vaccination program was estimated capable of annually avoiding 1 047 cases of invasive disease, 58 226 cases of pneumonia, and 209 862 cases of AOM. When herd immunity effects were considered, the program prevented 1.3 million cases of pneumococcal disease and over 7 000 pneumococcal deaths. At a vaccination cost of R$ 51.12 (US$ 26.35) per dose, vaccination would cost annually R$ 4 289 (US$ 2,211) per disability-adjusted life years averted. This does not take into account herd immunity effects. CONCLUSIONS: At the current vaccine price, conjugate vaccination could be a cost-effective investment compared to other options to control childhood diseases. Further analysis is required to determine whether vaccination at the current price is affordable to Brazil.
Authors: Chantal W B Boonacker; Pieter H Broos; Elisabeth A M Sanders; Anne G M Schilder; Maroeska M Rovers Journal: Pharmacoeconomics Date: 2011-03 Impact factor: 4.981
Authors: Marisa Holubar; Maria Christina Stavroulakis; Yvonne Maldonado; John P A Ioannidis; Despina Contopoulos-Ioannidis Journal: PLoS One Date: 2017-03-01 Impact factor: 3.240
Authors: Rohan Deogaonkar; Raymond Hutubessy; Inge van der Putten; Silvia Evers; Mark Jit Journal: BMC Public Health Date: 2012-10-16 Impact factor: 3.295
Authors: A J J M Oostvogels; G A De Wit; B Jahn; A Cassini; E Colzani; C De Waure; M E E Kretzschmar; U Siebert; N Mühlberger; M-J J Mangen Journal: Epidemiol Infect Date: 2014-12-12 Impact factor: 2.451
Authors: Sheila Elke Araujo Nunes; Ruth Minamisava; Maria Aparecida da Silva Vieira; Alexander Itria; Vicente Porfirio Pessoa; Ana Lúcia Sampaio Sgambatti de Andrade; Cristiana Maria Toscano Journal: Einstein (Sao Paulo) Date: 2017 Apr-Jun
Authors: Johnna Perdrizet; Carlos Felipe S Santana; Thais Senna; Rodrigo Fernandes Alexandre; Rodrigo Sini de Almeida; Julia Spinardi; Matt Wasserman Journal: Hum Vaccin Immunother Date: 2020-09-23 Impact factor: 3.452